Plasma nitric oxide and vascular endothelial growth factor levels in patients with metabolic syndrome and co-existing vascular complications;Stȩzenie tlenku azotu i naczyniowo- śródbłonkowego czynnika wzrostu w osoczu chorych na zespół metaboliczny ze współistnieja̧cymi powikłaniami naczyniowymi

Polski Merkuriusz Lekarski

Volumn 30, Issue 178, 2011, Pages 249-252

  Kowalski, Jan ^a   Śliwczyńska Rodziewicz, Dorota ^b   Kowalczyk, Edward ^a   Ciećwierz, Julita ^a   Irzmański, Robert ^a   Pawlicki, Lucjan ^a   Mejer, Anna ^a   Barylskl, Marcin ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Ophthalmology Ward   (Poland)

Author keywords

Metabolic syndrome; Nitric oxide; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; NITRIC OXIDE; VASCULOTROPIN A;

AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NITRIC OXIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957468421     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Barylski M., Kowalczyk E., Banach M. i wsp.: Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology, 2009, 60, 1, 87-92.
2. Bouloumié A., Bauersachs J., Linz W. i wsp.: Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension, 1997, 30, 934-941. (Pubitemid 27441125)
3. Caballero A. E., Arora S., Saouaf R. i wsp.: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes, 1999, 48, 1856-1862. (Pubitemid 29415208)
4. Celletti F. C., Waugh J. M., Amabile P. G., Brendolan A. i wsp.: Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med., 2001, 7, 425-429. (Pubitemid 32298544)
5. Cooke Jhon P.: Does ADMA Cause Endothelial Dysfunction? Arteriosclerosis, Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2032
6. Dembińska-Kieć A., Dulak J., Partyka Ł. i wsp.: VEGF-nitric oxide reciprocal regulation. Nat. Med., 1997, 3, 1177-1179.
7. Dulak J., Guevara I., Anna Zdzienicka A. i wsp.: Nitric Oxide Induces the Synthesis of Vascular Endothelial Growth Factor by Rat Vascular Smooth Muscle Cells. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 659-666. (Pubitemid 30151678)
8. Dulak J., Jozkowicz A., Frick M. i wsp.: Vascular endothelial growth factor angiogenesis, atherogenesis or both? J. Am. Coll. Cardiol., 2001, 38, 2137-2138. (Pubitemid 33116598)
9. Esper R. J., Nordaby R. A., Vilarino J. O. i wsp.: Endothelial dysfunction: a comprehensive appraisal. Cardiovasc. Diabetol., 2006, 5, 4-21.
10. Felmeden D. C., Spencer C. G., Belgore F. M. i wsp.: Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am. J. Hypertens., 2003, 16, 11-20. (Pubitemid 36078585)
11. Fomoni A., Raij L.: Metabolic syndrome and endothelial dysfunction. Curr. Hypertens. Rep., 2005, 7, 88-95. (Pubitemid 40796726)
12. Hsuech W. A., Quinones M. J.: Insulin resistance and the endothelium. Am. J. Med., 2004, 117, 109-117. (Pubitemid 38953731)
13. Inoue M., Itoh H., Uedea M. i wsp.: Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation, 1998, 98, 2108-2116 (Pubitemid 28527469)
14. Jansson P. A.: Endothelial dysfunction in insulin resistance and type 2 diabetes. J. Intern. Med., 2007, 262, 173-83
15. Kinalska I., Poplawska-Kita A., Kowalska I.: Wpływ otyłości na powikłania sercowo-naczyniowe w cukrzycy. Kardiodiabetologia, 2007, 3, 35-42.
16. Kowalski J., Barylski M., Ciecwierz J. i wsp.: Charakterystyka zespołu metabolicznego u osób bez chorób i chorobami układu sercowo-naczyniowego. Pol. Med. Lek., 2009, 27, 279-283.
17. Kowalski J., Krzemińska A., Banach M. i wsp.: The concentration of uric acid in patients with metabolic syndrome and cardiovascular disease. Centr. Eur. J. Med., 2009, 4, 272-278.
18. Liao J. K., Clark S. L.: Regulation of g-protein Ralpha in subunit expression by oxidized low density lipoprotein. J. Clin. Incest., 1995, 95, 1457-1463.
19. Libby P., Ridker P. M., Maseri A.: Inflammation and Atherosclerosis. Circulation, 2002, 105, 1135-1143. (Pubitemid 34212626)
20. Lim H. S., Blann A. D., Chong A. J. at all: Plasma vascular endothelial growth factor, angiopoetin-1 and angiopoetin-2 in diabetes. Diabetes Care, 2004, 27, 2918-2924.
21. Lteif A. A., Han K., Mather K. J.: Obesity, Insulin Resistance, and the Metabolic Syndrome. Determinants of Endothelial Dysfunction in Whites and Blacks. Circulation, 2005, 112, 32-38. (Pubitemid 40962566)
22. Münzel T., Heitzer T., Harrison D. G.: The physiology and pathophysiology of the nitric oxide/superoxide system. Herz, 1997, 22, 158-72. (Pubitemid 27282855)
23. Nakanishi K., Vinten-Johansen J., Lefer D. J. i wsp.: Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am. J. Physiol., 1992, 32, 1650-1658.
24. Pugh C. W., Ratcliffe P. J.: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003., 9, 677-684. (Pubitemid 36749216)
25. Quinoues M. J., Nicholas S. B., Lyon C. J.: Insulin resistance and the endothelium. Curr. Diab. Rep., 2005, 5, 246-253. (Pubitemid 41269588)
26. Rodrigez C. J., Mryake Y., Grahame-Clarke C. i wsp.: Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am. J. Cardiol., 2005, 96, 1273-1277. (Pubitemid 41505407)
27. Schachinger V., Britten M. B., Zeiher A. M.: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 2000, 101, 1899-1906. (Pubitemid 30225269)
28. Suwaidi J. A., Hamasaki S., Higano ST.: 2000 Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation, 2000, 101, 948-954. (Pubitemid 30131694)
29. Tolentino M. J., Tolentino M. J., Miller J. W. i wsp.: Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology, 1996, 103, 1820-1828 (Pubitemid 26403735)
30. Verma S., Anderson T. J.: Fundamentals of Endothelial Function for the Clinical Cardiologist. Circulation, 2002, 105, 546-549. (Pubitemid 34123425)
31. Vita J. A., Keaney J. F.: Endothelial Function. A Barometer for Cardiovascular Risk? Circulation, 2002, 106, 640-642. (Pubitemid 34851918)